Franciane Paul
Overview
Explore the profile of Franciane Paul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Planta C, Bret C, Manzoni D, Lhoumeau A, Mayeur Rousse C, Ticchioni M, et al.
BMJ Open
. 2024 Jun;
14(6):e081200.
PMID: 38889946
Introduction: Many patients referred for suspicion of myelodysplastic neoplasm (MDS) are subjected to unnecessary discomfort from bone marrow aspiration, due to the low disease prevalence in this population. Flow cytometric...
2.
Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz M, et al.
Ann Hematol
. 2024 Jan;
103(3):759-769.
PMID: 38273140
Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA...
3.
Gonzalez-Menendez P, Phadke I, Olive M, Joly A, Papoin J, Yan H, et al.
Blood
. 2023 Feb;
141(20):2520-2536.
PMID: 36735910
Metabolic programs contribute to hematopoietic stem and progenitor cell (HSPC) fate, but it is not known whether the metabolic regulation of protein synthesis controls HSPC differentiation. Here, we show that...
4.
Laloi L, Billotey N, Dumas P, Paul F, Villate A, Simand C, et al.
Cancer Med
. 2022 Dec;
12(6):7175-7181.
PMID: 36482507
Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at...
5.
Dumas P, Bertoli S, Bonmati C, Carre M, Lambert J, Ojeda-Uribe M, et al.
Leuk Res
. 2022 Jul;
120:106901.
PMID: 35872338
No abstract available.
6.
Picard M, Sterin A, Bay J, Courbon C, Moreau A, Paul F, et al.
Bull Cancer
. 2022 Jan;
110(2S):S123-S131.
PMID: 35094839
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is...
7.
Tudesq J, Yakoub-Agha M, Bay J, Courbon C, Paul F, Picard M, et al.
Bull Cancer
. 2021 Dec;
110(2S):S116-S122.
PMID: 34895696
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such...
8.
Paul F, Vicente C, Courbon C, Moreau A, Picard M, Pochon C, et al.
Bull Cancer
. 2021 Dec;
108(12S):S90-S97.
PMID: 34876272
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms...
9.
Gagez A, Paul F, Alaterre E, Gouilleux-Gruart V, Tuaillon E, Lepretre S, et al.
Leuk Lymphoma
. 2021 Nov;
62(13):3160-3169.
PMID: 34806520
Angiogenesis is in a constant balance between pro and anti-angiogenic factors. Neoangiogenesis, implicated in metastatic spreading is characterized in solid cancers, but fairly new in chronic lymphocytic leukemia (CLL). We...
10.
Pochon C, Courbon C, Bay J, Moreau A, Paul F, Picard M, et al.
Bull Cancer
. 2021 Nov;
108(12S):S98-S103.
PMID: 34802718
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell...